|
Hepatitis C
Virus Polymerase Inhibitors in Development
Structure-Based Design of Non-Nucleoside
NS5B Inhibitors for the Treatment of HCV
R. Than Hendricks, Ph.D., Principal Research Scientist, Medicinal
Chemistry, Roche Palo Alto
Hepatitis C
Virus Protease Inhibitors in Development
Discovery of the Macrocyclic HCV Protease
Inhibitor TMC435350
Pierre Raboisson, Ph.D., HCV Disease Area Chemistry Leader, Tibotec
BVBA
Discovery of MK-7009: A Novel Macrocyclic
Inhibitor of HCV NS3/4A Protease
Michael T. Rudd, Ph.D., Research Fellow, Medicinal Chemistry, Merck
Research Laboratories
Other
Mechanisms
A Peptide Inhibitor of the Hepatitis C Virus
Core Protein Dimerization
A. Donny Strosberg, Ph.D., Professor, Department of Infectology, The Scripps Research Institute-Florida
Taribavirin: Discovery and Development of
2nd Generation of Ribavirin for Treatment of HCV Infection
Jim Z. Wu, Ph.D., Director, Preclinical and Translational Research,
Global Drug Development, Valeant Pharmaceuticals International
|